Drug‑delivery technologies (galenic forms) offer a competitive advantage for pharmaceutical companies. They better meet the needs of patients, physicians, nurses, and pharmacists, while creating value for the broader healthcare system.

By reformulating existing active ingredients into more convenient dosage forms, branded manufacturers defend their franchises, generics companies enhance established products, and OTC players differentiate themselves in highly competitive markets — all while improving adherence and the patient experience.

1) Patient‑Centric Formulations: Clinical and Market Value

1.1. Galenic Innovations That Improve Use

• Pre‑measured doses: liquid stick packs and “on‑the‑go” formats that fit seamlessly into daily routines.
• Oral powders / powder stick packs: easy to carry, quick to reconstitute.
• Orodispersible tablets (ODT): ideal for patients with swallowing difficulties (pediatrics, geriatrics).
• Taste‑masking / particle coating: improves acceptability and supports adherence.
• Extended release (ER/LP): fewer doses, better tolerance.

SEO keywords included: galenic forms, drug‑delivery technologies, orodispersible tablets, liquid stick packs, taste masking, extended release, adherence.

1.2. Differentiation and Life‑Cycle Management

• Generics: differentiation in saturated markets through value‑added formulations.
• OTC: “premiumisation” thanks to convenient, patient‑centric formats that are less vulnerable to price wars.
• Rx (branded medicines): life‑cycle management before/during/after patent expiry (extra IP protection, improved patient experience).

“Value‑added medicines are a strong opportunity to differentiate our portfolio,” explains Robert Knerr (Stada).

2) Identifying Opportunities: Listening to the Field and Mapping Real Use

2.1. Point‑of‑Care Intelligence

• Field insights from physicians, nurses, pharmacists, patients.
• Expert and patient advisory boards to clarify perceived vs. real value.
• Local analysis: expectations vary by country and clinical practice.

Markus Weigandt (Merck KGaA): “Does your innovation address an important need?”

SEO keywords: patient feedback, prescriber insights, clinical adoption, perceived value.

2.2. Indications Suited to “On‑the‑Go” Formats

• Analgesics, antihistamines, antacids → unpredictable symptoms requiring fast, discreet administration.
• Powder and liquid formats = constant availability + ease of use.

2.3. Sources of Ideas: Patents, CDMOs, Open Innovation

• Patent monitoring (patent expiry) → reformulation opportunities.
• Pharmaceutical CDMOs: multi‑technology access, speed, cost reduction.
• Agnostic approach (internal/external): “We focus on the quality of the idea.”

3) CDMOs: The Key Partner in Galenic Innovation

3.1. Why Outsource?

• Cover internal technology gaps.
• Access specialized platforms (ODT, ER, micro‑encapsulation, taste masking).
• Faster time‑to‑market, lower CAPEX.

Sandoz: “We cannot excel in every domain.”

3.2. How to Select the Right CDMO

• Reliability, quality, compliance (GxP, regulatory files).
• Technological expertise with proven references (clinical/commercial batches).
• Industrial capabilities (scale‑up, validation, supply chain).
• Strong co‑development culture.

Key point: CDMO size is not decisive — delivery capability is.

4) From Concept to Market Success: Aligning Value and Adoption

4.1. Prescription Market (Rx): Convincing Multiple Decision‑Makers

• Centralized payers → cost constraints may outweigh usage benefits.
• Paradoxical incentives (e.g., injection revenues vs. more convenient forms).
• Need for a robust value dossier: adherence, quality of life, outcomes, total cost of care.

4.2. OTC Market: Education and Brand Awareness

• The consumer decides… only if they know the format exists.
• Stick‑packs: awareness still low → need for pharmacy education, usage visuals, sampling.
• Brand power is essential for selling incremental improvements.

5) Trends & Perspectives: The Rise of Patient‑Centric Forms

5.1. Health Systems Becoming More Open to Value‑of‑Use

• Nordic countries: patient and clinician input integrated into purchasing decisions.
• Higher likelihood of adopting convenient, quality‑of‑life‑enhancing formulations.

5.2. Adherence = Better Outcomes

• Simple, practical forms improve medication adherence, leading to better clinical outcomes and lower costs.
• A core argument in pharmacoeconomic dossiers.

5.3. What Will Accelerate

• Competitive pressure → stronger galenic differentiation.
• OTC: on‑the‑go formats, ODT, taste‑masking.
• Rx: extended release, combinations, post‑patent management.
• CDMOs: growing role in co‑development.

SEO keywords: market adoption, patient education, pharmacist role, proof of use, OTC premiumisation.